Neumora Therapeutics (NMRA) Current Assets (2022 - 2026)

Neumora Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $153.4 million for Q1 2026.

• On a quarterly basis, Current Assets fell 39.8% year-over-year to $153.4 million in Q1 2026; TTM through Mar 2026 was $153.4 million, a 39.8% decrease from a year earlier, with the FY2025 full-year figure at $190.5 million, down 39.33% from the prior year.
• Current Assets slipped to $153.4 million in Q1 2026 per NMRA's latest filing, from $190.5 million in the prior quarter.
• Across five years, Current Assets topped out at $525.7 million in Q3 2023 and bottomed at $153.4 million in Q1 2026.
• The 5-year median for Current Assets is $331.3 million (2024), against an average of $324.5 million.
• Across the five-year window, Current Assets gained 23.28% in 2023 and slumped 49.2% in 2025, its largest moves.
• Year by year, Current Assets stood at $388.0 million in 2022, then advanced by 23.28% to $478.3 million in 2023, then sank by 34.34% to $314.1 million in 2024, then sank by 39.33% to $190.5 million in 2025, then declined by 19.47% to $153.4 million in 2026.
• Per Business Quant, the three latest NMRA Current Assets figures stand at $153.4 million (Q1 2026), $190.5 million (Q4 2025), and $177.1 million (Q3 2025).